CA2497180A1 - Treatment of metastatic breast cancer with anthracyclines, taxanes and an histamine antagonist - Google Patents

Treatment of metastatic breast cancer with anthracyclines, taxanes and an histamine antagonist Download PDF

Info

Publication number
CA2497180A1
CA2497180A1 CA002497180A CA2497180A CA2497180A1 CA 2497180 A1 CA2497180 A1 CA 2497180A1 CA 002497180 A CA002497180 A CA 002497180A CA 2497180 A CA2497180 A CA 2497180A CA 2497180 A1 CA2497180 A1 CA 2497180A1
Authority
CA
Canada
Prior art keywords
administered
chemotherapeutic agent
patient
group
diphenyl compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002497180A
Other languages
English (en)
French (fr)
Inventor
Lorne J. Brandes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Manitoba
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2497180A1 publication Critical patent/CA2497180A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002497180A 2002-09-04 2003-09-03 Treatment of metastatic breast cancer with anthracyclines, taxanes and an histamine antagonist Abandoned CA2497180A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40767902P 2002-09-04 2002-09-04
US60/407,679 2002-09-04
PCT/CA2003/001340 WO2004022040A2 (en) 2002-09-04 2003-09-03 Treatment of metastatic breast cancer with anthracyclines, taxanes and an histamine antagonist

Publications (1)

Publication Number Publication Date
CA2497180A1 true CA2497180A1 (en) 2004-03-18

Family

ID=31978506

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002497180A Abandoned CA2497180A1 (en) 2002-09-04 2003-09-03 Treatment of metastatic breast cancer with anthracyclines, taxanes and an histamine antagonist

Country Status (11)

Country Link
US (1) US20060089317A1 (https=)
EP (1) EP1536779A2 (https=)
JP (1) JP2006516533A (https=)
KR (1) KR20050086415A (https=)
CN (1) CN1694691A (https=)
AU (1) AU2003266047A1 (https=)
BR (1) BR0314097A (https=)
CA (1) CA2497180A1 (https=)
MX (1) MXPA05002465A (https=)
RU (1) RU2005109421A (https=)
WO (1) WO2004022040A2 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2063574T3 (es) * 1990-12-17 1995-01-01 Univ Manitoba Metodo de tratamiento mejorado para el cancer.
GB9303210D0 (en) * 1993-02-17 1993-03-31 Univ Manitoba Cancer treatment
PL369792A1 (en) * 2001-11-01 2005-05-02 Ym Biosciences, Inc. Use of n,n-diethyl-2-[-4-(phenylmethyl)-phenoxy]ethanamine monohydrochloride (dppe) in cancer therapy
US20050119263A1 (en) * 2001-11-09 2005-06-02 Vincent Mark D. Treatment of breast cancer

Also Published As

Publication number Publication date
EP1536779A2 (en) 2005-06-08
KR20050086415A (ko) 2005-08-30
JP2006516533A (ja) 2006-07-06
AU2003266047A8 (en) 2004-03-29
WO2004022040A2 (en) 2004-03-18
BR0314097A (pt) 2005-07-19
CN1694691A (zh) 2005-11-09
AU2003266047A1 (en) 2004-03-29
MXPA05002465A (es) 2005-12-14
RU2005109421A (ru) 2005-10-20
WO2004022040A3 (en) 2004-04-29
US20060089317A1 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
Wolff et al. A Phase II study of the polyamine analog N 1, N 11-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast cancer
US8003105B2 (en) Method of treating cancer by co-administration of anticancer agents
AU2003244646B2 (en) Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
Morgan Jr et al. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics
Hahm et al. Combination of standard cytotoxic agents with polyamine analogues in the treatment of breast cancer cell lines
KR20120008069A (ko) 카바지탁셀 및 카페시타빈을 포함하는 항종양 조합물
JP2000505796A (ja) エダトレキセートおよびタキサン誘導体（例えばパクリタキセル）を用いる癌を処置するための組み合わせ治療方法
CA2497180A1 (en) Treatment of metastatic breast cancer with anthracyclines, taxanes and an histamine antagonist
US20050119263A1 (en) Treatment of breast cancer
US20080318880A1 (en) Neoadjuvant treatment of Breast Cancer
WO2004022044A1 (en) Use of a combination of a taxane with dppe for the treatment of cancer
US20060142287A1 (en) Use of a combination of dppe with other chemotherapeutic agents for the treatment of breast cancer
AU2002340668A1 (en) Treatment of breast cancer
ZA200508696B (en) Use of irinotecan for treatment of resistant breast cancer
Merlin et al. Comparison of P-glycoprotein expression and daunorubicin cellular accumulation in adult and childhood acute leukemias
Inbar et al. Chemofiltration (CF) for locally advanced cancer
Cummings et al. Positive correlation between tumour drug disposition and the activity of doxorubicin microspheres: Implications for the drugs in vivo mechanism of action
Merlin et al. Comparative evaluation of S9788, verapamil and cyclosporine a on multidrug resistant cells from patients with hematological malignancies
Kaburagi et al. Alternative daily subcutaneous injections of4ig/kg lenograstim in lung cancer case

Legal Events

Date Code Title Description
FZDE Discontinued